<DOC>
	<DOCNO>NCT02040779</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled parallel-group study . Participants randomly assign receive treatment beclomethasone dipropionate dosage 80 160 mcg/day deliver via Breath-Actuated Inhaler ( BAI ) ; match BAI placebo , 1:1:1 ratio 14- 21-day run-in period . Participants investigator remain blinded randomize treatment assignment study . The study consist 3 period : - run-in period : Screening visit ( SV ) randomization visit ( RV ) , 14-21 day ( 2-3 week ) prior study start - double-blind treatment period : RV final treatment visit , 85±3 day 12 week study start . - follow-up period : follow-up visit/telephone call , 7±3 day treatment period end .</brief_summary>
	<brief_title>A 12-week Safety Efficacy Study Beclomethasone Dipropionate ( 80 160 mcg/Day ) Delivered Via Breath-Actuated Inhaler ( BAI ) Patients &gt; =12 Years Old With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Severity Disease : The patient persistent asthma , force expiratory volume 1 second ( FEV1 ) 40 % 85 % value predict age , height , sex , race per National Health Nutrition Examination Survey ( NHANES III ) reference value screen visit ( SV ) ( Hankinson et al 1999 ) . Current asthma therapy : The patient currently treat 1 following : 1 ) inhale corticosteroid ( ICSs ) stable daily dose less equal 220 mcg/day fluticasone propionate via meter dose inhaler ( MDI ) equivalent minimum 4 week ( 28 day ) screen visit , 2 ) stable daily dosage noncorticosteroid therapy , include leukotriene modifier , theophylline , chromones , shortacting beta2 agonist ( SABAs ) alone combination minimum 4 week ( 28 day ) screen visit ( SV ) . Reversibility disease : The patient demonstrate least 15 % least 200 mL increase baseline FEV1 ( patient age 18 older ) within 30 minute 24 inhalation albuterol/salbutamol hydrofluoroalkane ( HFA ) MDI ( 90 mcg exactuator ) equivalent SV retesting . Other criterion apply , please contact investigator information The patient history lifethreatening asthma , define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest , hypoxic seizure . The patient pregnant lactate female plan become pregnant . The patient know hypersensitivity corticosteroid excipients study drug rescue medication formulation . The patient currently smoke smoke history 10 packyears ( packyear define smoke 1 pack cigarettes/day 1 year ) . The patient may use tobacco product within past year . The patient asthma exacerbation require oral corticosteroid within 1 month SV , hospitalization asthma within 2 month SV . The patient historical current evidence clinically significant disease . Significant disease define disease medical judgment investigator would put safety patient risk participation could affect efficacy safety analysis disease/condition worsen study . Other criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>asthma</keyword>
	<keyword>breath-actuated inhaler</keyword>
	<keyword>beclomethasone</keyword>
</DOC>